Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained?
<h3>Background</h3><p dir="ltr">No previous study assessed the outcomes of sleeve gastrectomy (SG) beyond 5 years among adult patients with type 2 diabetes (T2DM). We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.</p><h3>Methods</h3>&...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513538617245696 |
|---|---|
| author | Wahiba Elhag (5245547) |
| author2 | Isra Elgenaied (14151867) Merilyn Lock (9440240) Walid El Ansari (93732) |
| author2_role | author author author |
| author_facet | Wahiba Elhag (5245547) Isra Elgenaied (14151867) Merilyn Lock (9440240) Walid El Ansari (93732) |
| author_role | author |
| dc.creator.none.fl_str_mv | Wahiba Elhag (5245547) Isra Elgenaied (14151867) Merilyn Lock (9440240) Walid El Ansari (93732) |
| dc.date.none.fl_str_mv | 2025-03-14T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1007/s11695-024-07664-w |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Sleeve_Gastrectomy_in_Patients_with_Type_2_Diabetes_Anthropometric_and_Cardiometabolic_Improvements_at_1_3_5_7_and_9_years_Are_the_Initial_Benefits_Sustained_/30197815 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Sleeve gastrectomy Long-term outcomes Type 2 diabetes remission Diabetes recurrence Weight regain |
| dc.title.none.fl_str_mv | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">No previous study assessed the outcomes of sleeve gastrectomy (SG) beyond 5 years among adult patients with type 2 diabetes (T2DM). We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.</p><h3>Methods</h3><p dir="ltr">This is a retrospective study of 361 consecutive T2DM patients who underwent SG at our institution (April 2011–December 2015). Postoperative data were compared to baseline and to previous time points using paired t tests. Diabetes status was also assessed at each time point.</p><h3>Results</h3><p dir="ltr">The sample consisted of 65.37% females. The mean preoperative age was 44.38 ± 9.50 years and body mass index (BMI) was 43.81 ± 6.98 kg/m<sup>2</sup>. Generally, most improvements occurred in the first year and were sustained on the long term. Postoperatively, there was a significant and sustained weight reduction, amounting to a mean decrease of 9 kg/m<sup>2</sup> in BMI at year 9 and associated excess weight loss between 59%<sub>year</sub> 1 and 46%<sub>year</sub> 9. Fasting blood glucose decreased significantly across the five time points, from 9.27 ± 4.11preop to 7.06 ± 2.70 <sub>year9 </sub>mmol/L. Mean HbA1c significantly decreased from 8.1%preop to 6.77%<sub>year 9</sub>. The prevalence of complete remission of T2DM was 20.45%, 19.44%, and 20% at 5, 7, and 9 years respectively, with significant reductions in percentages of patients using diabetes medications or insulin. Between 10% and 23% of patients experienced relapse of T2DM by 5–9 years. In comparison to baseline levels, mean blood pressure, triglycerides, high-density lipoprotein, low-density lipoprotein, total cholesterol, and hepatic enzymes levels all showed improvement in the long term.</p><h3>Conclusion</h3><p dir="ltr">Patients with T2DM experienced substantial improvements in most anthropometric and cardiometabolic outcomes within the first year, and these were sustained in the long term.</p><h2>Other Information</h2><p dir="ltr">Published in: Obesity Surgery<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s11695-024-07664-w" target="_blank">https://dx.doi.org/10.1007/s11695-024-07664-w</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_80ac628290ae8745603f69e68490bd2b |
| identifier_str_mv | 10.1007/s11695-024-07664-w |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30197815 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained?Wahiba Elhag (5245547)Isra Elgenaied (14151867)Merilyn Lock (9440240)Walid El Ansari (93732)Biomedical and clinical sciencesClinical sciencesMedical biochemistry and metabolomicsSleeve gastrectomyLong-term outcomesType 2 diabetes remissionDiabetes recurrenceWeight regain<h3>Background</h3><p dir="ltr">No previous study assessed the outcomes of sleeve gastrectomy (SG) beyond 5 years among adult patients with type 2 diabetes (T2DM). We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.</p><h3>Methods</h3><p dir="ltr">This is a retrospective study of 361 consecutive T2DM patients who underwent SG at our institution (April 2011–December 2015). Postoperative data were compared to baseline and to previous time points using paired t tests. Diabetes status was also assessed at each time point.</p><h3>Results</h3><p dir="ltr">The sample consisted of 65.37% females. The mean preoperative age was 44.38 ± 9.50 years and body mass index (BMI) was 43.81 ± 6.98 kg/m<sup>2</sup>. Generally, most improvements occurred in the first year and were sustained on the long term. Postoperatively, there was a significant and sustained weight reduction, amounting to a mean decrease of 9 kg/m<sup>2</sup> in BMI at year 9 and associated excess weight loss between 59%<sub>year</sub> 1 and 46%<sub>year</sub> 9. Fasting blood glucose decreased significantly across the five time points, from 9.27 ± 4.11preop to 7.06 ± 2.70 <sub>year9 </sub>mmol/L. Mean HbA1c significantly decreased from 8.1%preop to 6.77%<sub>year 9</sub>. The prevalence of complete remission of T2DM was 20.45%, 19.44%, and 20% at 5, 7, and 9 years respectively, with significant reductions in percentages of patients using diabetes medications or insulin. Between 10% and 23% of patients experienced relapse of T2DM by 5–9 years. In comparison to baseline levels, mean blood pressure, triglycerides, high-density lipoprotein, low-density lipoprotein, total cholesterol, and hepatic enzymes levels all showed improvement in the long term.</p><h3>Conclusion</h3><p dir="ltr">Patients with T2DM experienced substantial improvements in most anthropometric and cardiometabolic outcomes within the first year, and these were sustained in the long term.</p><h2>Other Information</h2><p dir="ltr">Published in: Obesity Surgery<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s11695-024-07664-w" target="_blank">https://dx.doi.org/10.1007/s11695-024-07664-w</a></p>2025-03-14T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s11695-024-07664-whttps://figshare.com/articles/journal_contribution/Sleeve_Gastrectomy_in_Patients_with_Type_2_Diabetes_Anthropometric_and_Cardiometabolic_Improvements_at_1_3_5_7_and_9_years_Are_the_Initial_Benefits_Sustained_/30197815CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/301978152025-03-14T09:00:00Z |
| spellingShingle | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? Wahiba Elhag (5245547) Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Sleeve gastrectomy Long-term outcomes Type 2 diabetes remission Diabetes recurrence Weight regain |
| status_str | publishedVersion |
| title | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| title_full | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| title_fullStr | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| title_full_unstemmed | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| title_short | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| title_sort | Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? |
| topic | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Sleeve gastrectomy Long-term outcomes Type 2 diabetes remission Diabetes recurrence Weight regain |